EuReCa ONE—27 Nations, ONE Europe, ONE Registry A prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe

AbstractIntroductionThe aim of the EuReCa ONE study was to determine the incidence, process, and outcome for out of hospital cardiac arrest (OHCA) throughout Europe.MethodsThis was an international, prospective, multi-centre one-month study. Patients who suffered an OHCA during October 2014 who were attended and/or treated by an Emergency Medical Service (EMS) were eligible for inclusion in the study. Data were extracted from national, regional or local registries.ResultsData on 10,682 confirmed OHCAs from 248 regions in 27 countries, covering an estimated population of 174 million. In 7146 (66%) cases, CPR was started by a bystander or by the EMS. The incidence of CPR attempts ranged from 19.0 to 104.0 per 100,000 population per year. 1735 had ROSC on arrival at hospital (25.2%), Overall, 662/6414 (10.3%) in all cases with CPR attempted survived for at least 30 days or to hospital discharge.ConclusionThe results of EuReCa ONE highlight that OHCA is still a major public health problem accounting for a substantial number of deaths in Europe.EuReCa ONE very clearly demonstrates marked differences in the processes for data collection and reported outcomes following OHCA all over Europe. Using these data and analyses, different countries, regions, systems, and concepts can benchmark themselves and may learn from each other to further improve survival following one of our major health care events

Settings

Settings applied at each step of the protocol.</p

Step 7.4

Fibrosis detection.A. Interface of the "fibrosis detection" tool.B. Binary masks of fibrosis in samples:Mouse lung slice stained with MT (baseline sample);Mouse lung slice stained with MT (bleomycin-induced fibrosis sample);Mouse lung slice stained with SR (baseline sample);Mouse lung slice stained with SR (bleomycin-induced fibrosis sample).</p

Step 3.4

Border definition.A. Interface of the "border definition" tool.B. Binary masks of the borders of the samples:Mouse lung slice stained with MT (baseline sample);Mouse lung slice stained with MT (bleomycin-induced fibrosis sample);Mouse lung slice stained with SR (baseline sample);Mouse lung slice stained with SR (bleomycin-induced fibrosis sample).</p

Step 8.4

Fibrosis cleaning.A. Interface of the "fibrosis filter" automatic tool.B. Binary masks of filtered fibrosis in samples:Mouse lung slice stained with MT (baseline sample);Mouse lung slice stained with MT (bleomycin-induced fibrosis sample);Mouse lung slice stained with SR (baseline sample);Mouse lung slice stained with SR (bleomycin-induced fibrosis sample).</p

Step 2.10

Background cleaning.A. Interface of the "particle filter" automatic and manual tools.B. Cleaned binary masks of samples:Mouse lung slice stained with MT (baseline sample);Mouse lung slice stained with MT (bleomycin-induced fibrosis sample);Mouse lung slice stained with SR (baseline sample);Mouse lung slice stained with SR (bleomycin-induced fibrosis sample).</p

Step 12

Results.Quantification of fibrosis extend and airspace availability in the benchmark dataset (all samples).</p

Step 4.10

Air ducts walls definition.A. Interface of the "air ducts walls definition" tool.B. Overlays of samples, identified air ducts, and defined air ducts walls:Mouse lung slice stained with MT (baseline sample);Mouse lung slice stained with MT (bleomycin-induced fibrosis sample);Mouse lung slice stained with SR (baseline sample);Mouse lung slice stained with SR (bleomycin-induced fibrosis sample).</p

Step 1.1

Representative samples.Mouse lung slice stained with MT (baseline sample);Mouse lung slice stained with MT (bleomycin-induced fibrosis sample);Mouse lung slice stained with SR (baseline sample);Mouse lung slice stained with SR (bleomycin-induced fibrosis sample).</p

Step 10.3

Airspace quantification.A. Interface of the "airspace detection" tool.B. Binary masks of airspace in samples:Mouse lung slice stained with MT (baseline sample);Mouse lung slice stained with MT (bleomycin-induced fibrosis sample);Mouse lung slice stained with SR (baseline sample);Mouse lung slice stained with SR (bleomycin-induced fibrosis sample).</p